LEVOCARNITINE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Levocarnitine, and when can generic versions of Levocarnitine launch?
Levocarnitine is a drug marketed by Am Regent, Hikma, Teva Pharms Usa, Lyne, Novitium Pharma, Saptalis Pharms, and Rising. and is included in nine NDAs.
The generic ingredient in LEVOCARNITINE is levocarnitine. There are four drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the levocarnitine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Levocarnitine
A generic version of LEVOCARNITINE was approved as levocarnitine by HIKMA on March 29th, 2001.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LEVOCARNITINE?
- What are the global sales for LEVOCARNITINE?
- What is Average Wholesale Price for LEVOCARNITINE?
Summary for LEVOCARNITINE
US Patents: | 0 |
Applicants: | 7 |
NDAs: | 9 |
Finished Product Suppliers / Packagers: | 7 |
Raw Ingredient (Bulk) Api Vendors: | 111 |
Clinical Trials: | 23 |
Patent Applications: | 3,599 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for LEVOCARNITINE |
What excipients (inactive ingredients) are in LEVOCARNITINE? | LEVOCARNITINE excipients list |
DailyMed Link: | LEVOCARNITINE at DailyMed |
![LEVOCARNITINE drug patent expirations Drug patent expirations by year for LEVOCARNITINE](/p/graph/s/t/LEVOCARNITINE-patent-expirations.png)
![Drug Prices for LEVOCARNITINE](/p/graph/drug-price/LEVOCARNITINE.png)
Recent Clinical Trials for LEVOCARNITINE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Children's Oncology Group | Phase 3 |
Children's Hospital of Orange County | Early Phase 1 |
University of California, Irvine | Early Phase 1 |
Pharmacology for LEVOCARNITINE
Drug Class | Carnitine Analog |
Anatomical Therapeutic Chemical (ATC) Classes for LEVOCARNITINE
US Patents and Regulatory Information for LEVOCARNITINE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Am Regent | LEVOCARNITINE | levocarnitine | INJECTABLE;INJECTION | 075861-001 | Jun 22, 2001 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Saptalis Pharms | LEVOCARNITINE | levocarnitine | SOLUTION;ORAL | 212533-001 | Nov 10, 2021 | AA | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Hikma | LEVOCARNITINE | levocarnitine | SOLUTION;ORAL | 077399-001 | Oct 25, 2007 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Novitium Pharma | LEVOCARNITINE | levocarnitine | TABLET;ORAL | 216384-001 | Dec 9, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Hikma | LEVOCARNITINE | levocarnitine | INJECTABLE;INJECTION | 075567-001 | Mar 29, 2001 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Teva Pharms Usa | LEVOCARNITINE | levocarnitine | INJECTABLE;INJECTION | 075881-001 | Mar 29, 2001 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |